I haven't listened to the call but I wonder if there was an overreaction on the downside. The successful results, and all of the related hype to-date, for Dirucotide have occurred in secondary progressive MS. The results in that population group have clearly been positive as far as primary endpoints. I believe this was the first trial to test if the drug would work in relapsing-remitting MS.
So, if the drug shows successful results in Phase III for SPMS, similar to what it has already shown, the stock should clearly rebound. I have no skin in the game on this one as it's just too risky being essentially an all-or-nothing bet on Dirucotide.
Market Data 
Markets 
AI
